Trial reportPloS one2016
Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00802919 (Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study), which is not on this map. Cited by 43 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors, Independent Investigator Study
Who cites it
43 citing papers in PubMed, 9 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Efficacy and safety of anti-inflammatory drug-assisted treatment of symptoms in patients with schizophrenia: a meta-analysis.BMC psychiatry · 2026Pooled it
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.Expert opinion on pharmacotherapy · 2020Pooled it
- Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Pooled it
- An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.Psychological medicine · 2019Pooled it
- Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis.BMC psychiatry · 2017Pooled it
- Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2017Pooled it
- Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.Addiction (Abingdon, England) · 2016Pooled it
- The effect of varenicline on mood and cognition in smokers with HIV.Psychopharmacology · 2020Trial
- Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder.Schizophrenia research · 2017Trial
- Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy.Journal of dual diagnosisTrial
- Anti-inflammatory and antioxidant effects of Lavandula stoechas L. on human macrophages and in silico prediction of α7 nicotinic acetylcholine receptor interaction.BMC complementary medicine and therapies · 2026Article
- A new framework for nicotinic receptor-targeted therapeutic strategies in psychiatric and neurodegenerative disorders.Frontiers in cellular neuroscience · 2026Article
- Smoking cessation for people with severe mental illness: systematic review and network meta-analysis.BMJ medicine · 2026Article
- Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024.F1000Research · 2025Article
- Interventions for smoking cessation in inpatient psychiatry settings.The Cochrane database of systematic reviews · 2024Article
- Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.Neuropsychopharmacology reports · 2024Review
- Tobacco use disorder in patients with other mental disorders: a dual disorder perspective from clinical neuroscience.Frontiers in psychiatry · 2024Review
- Trends in cigarette use and health insurance coverage among US adults with mental health and substance use disorders.Addiction (Abingdon, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 10 institutions in 3 countries.
Funding
Abstract
unlabelledSchizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effective as an antismoking drug in cigarette smokers, although concerns have been raised about potential psychiatric side-effects. We conducted a double-blind placebo controlled study in 87 schizophrenic smokers to evaluate the effects of varenicline (2 mg/day) on measures of smoking, cognition, psychiatric symptoms, and side-effects in schizophrenic patients who were cigarette smokers. Varenicline significantly decreased cotinine levels (P<0.001), and other objective and subjective measures of smoking (P < .01), and responses on a smoking urges scale (P = .02), more than placebo. Varenicline did not improve scores on a cognitive battery designed to test the effect of drugs on cognitive performance in schizophrenia (the MATRICS battery), either in overall MATRICS battery Composite or individual Domain scores, more than placebo. There were no significant differences between varenicline vs. placebo effects on total symptom scores on psychiatric rating scales, PANSS, SANS, or Calgary Depression scales, and there were no significant drug effects in any of these scales sub-scores when we used Benjamin-Hochberg corrected significance levels (α = .05). Varenicline patients did not show greater side-effects than placebo treated patients at any time point when controlled for baseline side-effect scores. Our study supports the use of varenicline as a safe drug for smoking reduction in schizophrenia but not as a cognitive enhancer.
trial registrationClinicalTrials.gov 00802919.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.